Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Focal Segmental Glomerulosclerosis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43883   clinical trials with a EudraCT protocol, of which   7296   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    27 result(s) found for: Focal Segmental Glomerulosclerosis. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2012-002365-35 Sponsor Protocol Number: GC1008FSGS03110 Start Date*: 2013-07-15
    Sponsor Name:Genzyme Corporation
    Full Title: A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients with Steroid-Resistant Primary Focal Segmental Glomerulosclerosis
    Medical condition: Focal segmental glomerulosclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10067757 Focal segmental glomerulosclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-003607-35 Sponsor Protocol Number: C0221002 Start Date*: 2020-10-26
    Sponsor Name:Pfizer Inc.
    Full Title: PHASE 2, 24-WEEK, ADAPTIVE, OPEN LABEL, SEQUENTIAL COHORT TRIAL TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06730512 FOLLOWING MULTIPLE DOSES IN ADULT SUBJECTS WITH FO...
    Medical condition: Focal Segmental Glomerulosclerosis (FSGS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10067757 Focal segmental glomerulosclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SK (Completed) PL (Completed) CZ (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-004174-64 Sponsor Protocol Number: DMX-200-301 Start Date*: 2022-03-08
    Sponsor Name:Dimerix Bioscience Pty Ltd
    Full Title: A pivotal Phase 3, multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS) who are receiving...
    Medical condition: Focal segmental glomerulosclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10067757 Focal segmental glomerulosclerosis PT
    21.1 10038359 - Renal and urinary disorders 10016832 Focal & segmental glomerulosclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000384-23 Sponsor Protocol Number: 1434-0004 Start Date*: 2022-05-31
    Sponsor Name:BOEHRINGER-INGELHEIM ITALIA S.P.A.
    Full Title: A multicenter, randomized, double-blind, parallel group, placebo controlled study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of BI 764198 administered orally once daily f...
    Medical condition: Glomerulosclerosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing) ES (Ongoing) IE (Ongoing) DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-002358-38 Sponsor Protocol Number: RET-D-001 Start Date*: 2015-04-28
    Sponsor Name:Travere Therapeutics, Inc.
    Full Title: PROTOCOL RET-D-001: EFFICACY AND SAFETY OF SPARSENTAN (RE-021), A DUAL ENDOTHELIN RECEPTOR AND ANGIOTENSIN RECEPTOR BLOCKER, IN PATIENTS WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS): A RANDOMIZED...
    Medical condition: FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10067757 Focal segmental glomerulosclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) IT (Ongoing) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-016003-26 Sponsor Protocol Number: 1.0 Start Date*: 2010-05-06
    Sponsor Name:UHB NHS Foundation Trust
    Full Title: RANDOMISED PILOT TRIAL OF MYFORTIC FOR THE TREATMENT OF PRIMARY PROTEINURIC GLOMERULONEPHRITIS.
    Medical condition: Primary Proteinuric Glomeruolnephritis Focal segmental glomeruloscerosis and IgA nephropathy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10067757 Focal segmental glomerulosclerosis PT
    14.1 10038359 - Renal and urinary disorders 10021263 IgA nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-000185-42 Sponsor Protocol Number: VX19-147-101 Start Date*: 2020-06-01
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 2a, Open-label, Single-arm, 2-Part Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis.
    Medical condition: APOL1-mediated Focal segmental glomerulosclerosis (FSGS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10067757 Focal segmental glomerulosclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-003021-15 Sponsor Protocol Number: CL011_140 Start Date*: 2018-05-18
    Sponsor Name:ChemoCentryx, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects with Focal Segmental Glomerulosclerosis (FSGS)
    Medical condition: Focal Segmental Glomerulosclerosis (FSGS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10067757 Focal segmental glomerulosclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-004192-13 Sponsor Protocol Number: R3R01-ASFSGS-201 Start Date*: Information not available in EudraCT
    Sponsor Name:River 3 Renal, Corporation
    Full Title: A Phase II, Multi-center, Open-Label Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of R3R01 in Alport Syndrome Patients with Uncontrolled Proteinuria on ACE/ARB Inhibition and...
    Medical condition: Alport Syndrome (AS) and Primary Steroid-Resistent Focal Segmental Glomerulosclerosis (FSGS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10001843 Alport's syndrome PT
    21.1 10038359 - Renal and urinary disorders 10067757 Focal segmental glomerulosclerosis PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-006750-17 Sponsor Protocol Number: NEMO Start Date*: 2009-04-14
    Sponsor Name:IST. DI RICERCHE FARMACOLOG. M. NEGRI
    Full Title: A prospective, sequential study to assess the efficacy of rituximab therapy in maintaining remission of nephrotic syndrome after steroid and immunosuppressive therapy withdrawal in patients with st...
    Medical condition: Nephrotic Syndrome secondary to minimal change disease (MCD) or idiopathic focal and segmental glomerulosclerosis (FSGS.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029171 LLT
    9.1 10058326 LLT
    9.1 10016832 LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-000621-27 Sponsor Protocol Number: RTRX-RE021-201 Start Date*: 2022-10-20
    Sponsor Name:Travere Therapeutics, Inc.
    Full Title: A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Treatment in Pediatric Subjects with Selected Proteinuric Glomerular Diseases (E...
    Medical condition: Proteinuric glomerular diseases including: •Focal segmental glomerulosclerosis (FSGS) •Minimal change disease (MCD) •Immunoglobulin A nephropathy (IgAN) •Immunoglobulin A vasculitis (IgAV) •Al...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10067757 Focal segmental glomerulosclerosis PT
    20.0 10038359 - Renal and urinary disorders 10021263 IgA nephropathy PT
    22.1 100000004858 10082959 IgA vasculitis LLT
    20.0 10010331 - Congenital, familial and genetic disorders 10001843 Alport's syndrome PT
    21.1 10038359 - Renal and urinary disorders 10058326 Minimal change disease LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) ES (Temporarily Halted) SE (Restarted) PL (Ongoing) DE (Restarted) IT (Ongoing) NL (Restarted)
    Trial results: (No results available)
    EudraCT Number: 2005-004460-22 Sponsor Protocol Number: 5012005 Start Date*: 2006-05-12
    Sponsor Name:Hopital Erasme
    Full Title: Multicenter, pilot, open, randomized, parallel group study to evaluate the association of Neoral with ACE-inhibitors as compared to corticosteroids with ACE-inhibitors in the treatment of de novo n...
    Medical condition: focal and segmental glomerulosclerosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003022-32 Sponsor Protocol Number: CL012_140 Start Date*: 2019-10-12
    Sponsor Name:ChemoCentryx, Inc.
    Full Title: An Open Label, Intra-Subject Dose Escalation Study of CCX140-B in Subjects with Primary Focal Segmental Glomerulosclerosis (FSGS) and Nephrotic Syndrome
    Medical condition: Primary Focal Segmental Glomerulosclerosis (FSGS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10067757 Focal segmental glomerulosclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003366-27 Sponsor Protocol Number: R-SRNS17 Start Date*: 2017-12-21
    Sponsor Name:Radboud University Nijmegen Medical Center
    Full Title: Efficacy of rituximab in comparison to continued corticosteroid treatment in idiopathic nephrotic syndrome unresponsive to 8 weeks of high dose prednisone.
    Medical condition: Idiopathic nephrotic syndrome Focal segmental glomerulosclerosis Minimal change disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-005141-23 Sponsor Protocol Number: 021FSGS16010 Start Date*: 2018-09-18
    Sponsor Name:Retrophin, Inc.
    Full Title: A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients with...
    Medical condition: Focal segmental glomerulosclerosis (FSGS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10067757 Focal segmental glomerulosclerosis PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Ongoing) CZ (Ongoing) ES (Ongoing) PL (Ongoing) HU (Prematurely Ended) DK (Ongoing) EE (Ongoing) SE (Ongoing) PT (Ongoing) BE (Ongoing) HR (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-002004-33 Sponsor Protocol Number: FCRD01 Start Date*: 2007-08-15
    Sponsor Name:Encysive Pharmaceuticals Inc
    Full Title: The effects of sitaxsentan once daily dosing on proteinuria, 24 hour systemic blood pressure and arterial stiffness in subjects with chronic kidney disease.
    Medical condition: Chronic Kidney Disease (CKD)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-004176-18 Sponsor Protocol Number: CHK01-02 Start Date*: 2021-06-21
    Sponsor Name:Chinook Therapeutics U.S., Inc.
    Full Title: A Phase 2, Open-Label, Basket Study of Atrasentan in Patients with Proteinuric Glomerular Diseases (The AFFINITY Study)
    Medical condition: Proteinuric glomerular diseases, including: Immunoglobulin A nephropathy (IgAN) (with UPCR 0.5 to <1.0 g/g) Focal segmental glomerulosclerosis (FSGS) Alport Syndrome Diabetes kidney disease (DKD) (...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001365-26 Sponsor Protocol Number: AN-IGN3321 Start Date*: 2014-08-21
    Sponsor Name:Anthera Pharmaceuticals, Inc
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects with IgA Nephropathy
    Medical condition: IgA Nephropathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10021263 IgA nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) DE (Completed) IT (Prematurely Ended) HU (Completed) SE (Ongoing) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-005450-36 Sponsor Protocol Number: IM101-566 Start Date*: 2016-08-01
    Sponsor Name:Bristol-Myers Squibb Company
    Full Title: A Phase II Randomized, Placebo-Controlled, Double-Blind, Parallel Arms With Switchover, Pilot Study to Evaluate the Efficacy and Safety of Intravenous Abatacept in Treatment Resistant Nephrotic Syn...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2016-003198-17 Sponsor Protocol Number: UZB_20160728 Start Date*: 2016-09-29
    Sponsor Name:Universitair Ziekenhuis Brussel Vrije Universiteit Brussel
    Full Title: A Prospective Interventional Pilot Study on the Use of Valproic Acid for Treatment of Idiopathic Nephrotic Syndrome
    Medical condition: Treatment of Idiopathic Nephrotic Syndrome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 17:41:03 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA